ARCA biopharma, Inc. (ABIO) Financial Statements (2024 and earlier)

Company Profile

Business Address 10170 CHURCH RANCH WAY
WESTMINSTER, CO 80021
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments42,445,00053,359,00049,071,0008,363,0006,608,00011,752,000
Cash and cash equivalents42,445,00053,359,00049,071,0008,363,0006,608,0008,702,000
Short-term investments      3,050,000
Other current assets254,0001,062,000897,000117,000169,000547,000
Total current assets:42,699,00054,421,00049,968,0008,480,0006,777,00012,299,000
Noncurrent Assets
Operating lease, right-of-use asset343,000437,000428,00022,000
Property, plant and equipment25,00048,00021,00010,00024,00042,000
Other noncurrent assets18,00018,00012,00024,00024,00024,000
Total noncurrent assets:386,000503,000461,00056,00048,00066,000
TOTAL ASSETS:43,085,00054,924,00050,429,0008,536,0006,825,00012,365,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,132,0003,498,0003,499,000926,000793,0002,070,000
Employee-related liabilities925,000815,000129,000150,000757,000
Accounts payable334,0001,117,0001,773,000418,000230,000622,000
Accrued liabilities798,0001,456,000911,000379,000413,000691,000
Total current liabilities:1,132,0003,498,0003,499,000926,000793,0002,070,000
Noncurrent Liabilities
Long-term debt and lease obligation:  383,000409,000   
Liabilities, other than long-term debt280,000    20,000
Deferred revenue and credits20,000
Operating lease, liability280,000383,000409,000 
Other undisclosed noncurrent liabilities  (383,000)(409,000)   
Total noncurrent liabilities:280,000383,000409,000  20,000
Total liabilities:1,412,0003,881,0003,908,000926,000793,0002,090,000
Equity
Equity, attributable to parent41,673,00051,043,00046,521,0007,610,0006,032,00010,275,000
Common stock14,00014,00010,0002,00014,00012,000
Additional paid in capital225,061,000224,505,000200,665,000152,024,000144,952,000141,266,000
Accumulated other comprehensive loss      (2,000)
Accumulated deficit(183,402,000)(173,476,000)(154,154,000)(144,416,000)(138,934,000)(131,001,000)
Total equity:41,673,00051,043,00046,521,0007,610,0006,032,00010,275,000
TOTAL LIABILITIES AND EQUITY:43,085,00054,924,00050,429,0008,536,0006,825,00012,365,000

Income Statement (P&L) (USD)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Operating expenses(10,596,000)(19,335,000)(9,766,000)(5,814,000)(8,118,000)(18,712,000)
Operating loss:(10,596,000)(19,335,000)(9,766,000)(5,814,000)(8,118,000)(18,712,000)
Nonoperating expense
(Other Nonoperating expense)
 (5,000)     
Interest and debt expense   (9,000)(7,000)(8,000)(6,000)
Loss from continuing operations before equity method investments, income taxes:(10,601,000)(19,335,000)(9,775,000)(5,821,000)(8,126,000)(18,718,000)
Other undisclosed income from continuing operations before income taxes  13,00028,000172,000162,000167,000
Loss from continuing operations before income taxes:(10,601,000)(19,322,000)(9,747,000)(5,649,000)(7,964,000)(18,551,000)
Income tax benefit   9,000167,00031,00061,000
Loss from continuing operations:(10,601,000)(19,322,000)(9,738,000)(5,482,000)(7,933,000)(18,490,000)
Loss before gain (loss) on sale of properties:(19,322,000)(9,738,000)(5,482,000)(7,933,000)(18,490,000)
Net loss:(10,601,000)(19,322,000)(9,738,000)(5,482,000)(7,933,000)(18,490,000)
Other undisclosed net income attributable to parent675,000     
Net loss available to common stockholders, diluted:(9,926,000)(19,322,000)(9,738,000)(5,482,000)(7,933,000)(18,490,000)

Comprehensive Income (USD)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(10,601,000)(19,322,000)(9,738,000)(5,482,000)(7,933,000)(18,490,000)
Comprehensive loss:(10,601,000)(19,322,000)(9,738,000)(5,482,000)(7,933,000)(18,490,000)
Other undisclosed comprehensive income, net of tax, attributable to parent     2,00017,000
Comprehensive loss, net of tax, attributable to parent:(10,601,000)(19,322,000)(9,738,000)(5,482,000)(7,931,000)(18,473,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: